In general, PD-1/PD-L1 blockade (either as monotherapy or in combination with other anti-cancer drugs) does not seem to increase infection incidence (reporting OR 0.68; 95% CI: 0.67–0.7) [145]. The gene discussed is CD274; the disease is infection.